Inflammation

Items 181-190 of 196

per page
Set Descending Direction
  1. Shikonin
    CAS  517-89-5
    AG-CN2-0487
    AG-CN2-0487-M01010 mg
    CHF 60.00
    AG-CN2-0487-M05050 mg
    CHF 200.00
    Shikonin
  2. SIGIRR (human):Fc (human) (rec.)
    AG-40A-0093T
    AG-40A-0093T-C01010 µg
    CHF 170.00
    AG-40A-0093T-C05050 µg
    CHF 350.00
  3. ST2 (human):Fc (human) (rec.)
    AG-40A-0059
    AG-40A-0059-C05050 µg
    CHF 505.00
    Specific interaction of human ST2 (Prod. No. AG-40A-0059) with recombinant human IL-33. An indirect competitive ELISA was performed as follows; 1) coat microtiter plate wells with hST2-Fc (10μg/ml); 2) add a varying concentrations of hIL-33 with
  4. Talabostat . mesylate
    CAS  150080-09-4
    AG-CR1-3541
    AG-CR1-3541-M01010 mg
    CHF 80.00
    AG-CR1-3541-M05050 mg
    CHF 280.00
    Talabostat . mesylate
  5. Taspine
    CAS  602-07-3
    AG-CN2-0544
    AG-CN2-0544-M0011 mg
    CHF 95.00
    AG-CN2-0544-M0055 mg
    CHF 380.00
    AG-CN2-0544-M01010 mg
    CHF 600.00
    Taspine
  6. TDZD-8
    CAS  327036-89-5
    AG-CR1-3740
    AG-CR1-3740-M0055 mg
    CHF 60.00
    AG-CR1-3740-M02525 mg
    CHF 130.00
    TDZD-8
  7. Telaprevir
    CAS  402957-28-2
    AG-CR1-3741
    AG-CR1-3741-M01010 mg
    CHF 100.00
    AG-CR1-3741-M05050 mg
    CHF 300.00
    AG-CR1-3741-M250250 mg
    CHF 750.00
    Telaprevir
  8. Umifenovir . hydrochloride
    CAS  131707-23-8
    AG-CR1-3718
    AG-CR1-3718-M01010 mg
    CHF 60.00
    AG-CR1-3718-M05050 mg
    CHF 180.00
    AG-CR1-3718-M250250 mg
    CHF 540.00
    Umifenovir . hydrochloride
  9. Ursodeoxycholic acid
    CAS  128-13-2
    AG-CN2-0411
    AG-CN2-0411-G0011 g
    CHF 52.00
    AG-CN2-0411-G0055 g
    CHF 156.00
    Ursodeoxycholic acid
  10. Vincristine . sulfate
    CAS  2068-78-2
    AG-CN2-0446
    AG-CN2-0446-M0055 mg
    CHF 55.00
    AG-CN2-0446-M02525 mg
    CHF 180.00
    Vincristine . sulfate

Items 181-190 of 196

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.